Germany’s IQWiG Pans Pfizer’s Xalkori On Study Results, Side Effects
This article was originally published in The Pink Sheet Daily
Executive Summary
Germany’s IQWiG has shot down Pfizer’s lung cancer treatment, citing questionable study results and no improvement on curbing side effects.
You may also be interested in...
Pfizer Loses Fight To Persuade NICE Of Xalkori’s Cost-Effectiveness
Pfizer says that it won’t challenge NICE’s final rejection of Xalkori on cost-effectiveness and survival uncertainty grounds.
No Approval, No Pay: VCs Bet Large On Late-Stage Pharma Trials
Some of the biggest life science VCs are spending hundreds of millions of dollars to run the clinical trials of drugs owned by big drugmakers. But if the strategy works, they may have come up with a better way to diversify their portfolios in an era when long-term company-building isn’t paying off.
No Approval, No Pay: VCs Bet Large On Late-Stage Pharma Trials
Some of the biggest names in life science venture capital – OrbiMed Advisors, Clarus Ventures, and Abingworth – are spending hundreds of millions of dollars to run the clinical trials of drugs owned by Pfizer and other big drugmakers. They’re taking on major clinical and regulatory risks for what might be less-than-stellar returns but if it works, these VCs may have come up with a better way to diversify their portfolios in an era when long-term company-building isn’t paying off.